Non-Invasive Sensors & bioMEMS Offer Market Opps

According to Jérôme Mouly, Senior Technology & Market Analyst at Yole Développement (Yole), a new momentum is being generated from sensor makers responding to the current global healthcare transformation. Their innovations are opening paths to new business opportunities for mobile healthcare and emerging non-invasive devices. MEMS technology is playing a major role as the technology is mature enough to offer miniaturized and low power-consumption sensors, while meeting medical-grade requirements at an acceptable price.

 

Yole’s life sciences and healthcare report, “BioMEMS & Non-Invasive Sensors: Microsystems for Life Sciences & Healthcare 2018”, identifies threats and opportunities related to bioMEMS with promising technologies and booming applications, along with market and technology trends. It proposes a healthcare market segmentation dedicated to the MEMS devices. An overview of the main players at every level of the supply chain, including market shares is also well described. In addition, this 2018 edition reveals a relevant comparison of the BioMEMS market with the global MEMS market with similarities and differences.

Free Newsletter

Like this article? Subscribe to FierceSensors!

The sensors industry is constantly changing as innovation runs the market’s trends. FierceSensors subscribers rely on our suite of newsletters as their must-read source for the latest news, developments and analysis impacting their world. Register today to get sensors news and updates delivered right to your inbox.

 

Jérôme Mouly says, “The MEMS technology is consolidating its healthcare market penetration. MEMS products will continue their huge 14.9% growth for the next five years.”

 

More companies are showing a growing interest in the healthcare domain. In the past two to three years, Google, Apple, and Amazon have highlighted challenging projects, i.e. measuring blood glucose via smartwatches or smart lenses. Accordingly, sensor makers are developing new technologies and platforms to answer the specific requirements of medical grade products. Therefore, their aim is to avoid the strong constraint coming from implantable devices and related regulations. At the same time, it will bring comfort and ease of use for patients. This trend will so impact the bioMEMS non-invasive sensors market evolution in the coming years.

 

As per Yole, demand for MEMS devices is increasing exponentially thanks to a democratization of medical devices that’s bringing them closer to consumer and creating a high demand for portable and wearable devices enabling patient monitoring at the point of need. To satisfy demand, almost all MEMS foundries are proposing manufacturing services dedicated to healthcare applications.

 

With the addition of microfluidic chips including Si-based, polymer-based, and glass-based, the BioMEMS market, is expected to more than double. The consulting company announces a US$3 billion market in 2017. This figure should reach $6.9 billion in 2023, showing a14.9% CAGR from 2017 to 2023. This makes bioMEMS capabilities a must-have for today’s global sensor makers.

 

According to Yole, the leading MEMS devices are:

  • Microfluidics demand still drives the BioMEMS market thanks to point of care applications and an increasing demand for next generation sequencing”, announces Sébastien Clerc, Technology & Market Analyst from Yole.
  • Pressure sensors are more mature sensor devices used in respiratory and blood monitoring, still reaching volumes of several hundred million units per year. Nevertheless, these mature devices are expected to enjoy a new wave of interest thanks to fresh demand for smart connected objects like inhalers and sleep apnea monitoring systems.
  • Transformation of global healthcare is spurring strong efforts to acquire new functionalities and access to new diagnostic capabilities with micromachined ultra sound transducers including CMUT and PMUT, as well as gas sensors.
  • MEMS sensor innovation has triggered developments in neurotechnologies, with neural implants for therapeutic applications (still at research level today) paving the way for better quality-of-life for patients with neurodegenerative diseases.  

For more details, checkout the Yole “BioMEMS & Non-Invasive Sensors” report.

Suggested Articles

Amphenol Corp. reported today GAAP diluted earnings per share of $1.03 for the fourth quarter of 2019, compared to $1.09 for the 2018 fourth quarter.

Google CEO Sundar Pichai said EU's GDPR could be starting point for AI regulation, but urged countries to cooperate for a standard approach.

Apple's Lighting cable may be phased out, according to an article on the BBC site.